Neumora depression drug fails; EnGene to cut 50% of staff

Neumora’s stumble is the latest setback for a once-promising class of brain drugs. Elsewhere, a cell therapy manufacturing specialist took steps toward an IPO and J&J made its latest U.S investment.

By BioPharma Dive staff • June 16, 2026

[Podcast] (Season 2) The Progress Profile: Alzheimer’s Research in Focus

This podcast explores how leading Alzheimer’s experts are working to bridge the gap between clinical trial design and frontline care.

By BioPharma Dive's studioID • June 16, 2026

Explore the Trendline➔

Top 5 stories from BioPharma Dive

Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.

By BioPharma Dive staff

Medicare drug price rule may target under-the-skin Keytruda and Opdivo

For 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.

By Jonathan Gardner • June 15, 2026

Lilly scores early positive data for new JAK drug

Acquired through its purchase of Ajax, the drug showed encouraging effects in patients with hard-to-treat myelofibrosis. To analysts, such results could lead to competition for Incyte’s Jakafi.

By Jacob Bell • June 15, 2026

J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch

New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.

By BioPharma Dive staff • June 11, 2026

Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test

The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy. 

By Jonathan Gardner • June 11, 2026

Sanofi stops immune drug trial in latest research setback

The failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a potential blockbuster.

By Kristin Jensen • June 10, 2026

GSK boosts cancer pipeline with $11B Nuvalent buyout

The British drugmaker's third acquisition this year gives it two experimental lung cancer drugs under FDA review that it hopes will support a franchise.

By Jonathan Gardner • June 9, 2026

Roche stakes $700M on Nurix’s protein-degrading drug

Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.

By Ben Fidler • June 8, 2026

Precision under pressure: Logistic solutions for nuclear medicine scalability

Racing the clock: How precision logistics deliver life-saving nuclear medicine.

June 8, 2026

Generic drugmakers gain key victory in ‘skinny label’ patent case

The Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching implications for the availability of generics.

By Jonathan Gardner • June 5, 2026

Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?

While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.

By Kelly Bilodeau • June 5, 2026

Otsuka showcases kidney drug data; Pfizer cuts an AI deal

Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends and Axsome warded off generic competitors.

By BioPharma Dive staff • June 4, 2026

Eli Lilly issues data sharing ultimatum to 340B hospitals

Select hospitals have refused to share data to prove they’re not double-dipping drug discounts, Lilly said. Hospitals, which have until Monday to comply, are urging the government to intervene.

By Rebecca Pifer Parduhn • June 2, 2026

At ASCO, Merck makes case for a ‘cornerstone’ cancer drug

Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.

By Delilah Alvarado • May 29, 2026

Bristol Myers unveils data for one of its next-gen blood cancer drugs

Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.

By Jonathan Gardner • May 29, 2026

Pfizer, Innovent strike $10B cancer drug deal

Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.

By Ben Fidler • May 29, 2026

GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’

The findings supporting bepirovirsen were deemed a “historic moment” by physicians and validate a drug that has “clear blockbuster potential,” according to one analyst.

By Jonathan Gardner • May 28, 2026

CVS obesity drug deal puts Lilly on equal footing with Novo

The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk. 

By Kristin Jensen • May 28, 2026

Early data for heart drug affirm Lilly’s billion-dollar bet on Verve

The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.

By Jonathan Gardner • May 26, 2026

Lilly dives into vaccine research with 3 biotech buyouts

Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an infectious disease portfolio.

By Delilah Alvarado • May 26, 2026

Lilly’s triple-acting obesity drug hits goal in Phase 3 trial

Participants who stayed on the drug lost around one-quarter of their body weight, potentially setting a new benchmark for rivals like Novo Nordisk.

By Jonathan Gardner • May 21, 2026

In Alzheimer’s, Bristol Myers sees big promise beyond amyloid

Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.

By Jacob Bell • May 21, 2026

Bristol Myers deepens AI investment with Anthropic deal

The collaboration marks an “evolution” in the pharmaceutical giant’s use of AI and adds to a series of broad deals its peers have used to adopt the technology across many day-to-day activities.

By Kristin Jensen • May 20, 2026

Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update

Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antitrust suit.

By BioPharma Dive staff • May 20, 2026